Acute myeloid leukemia cell (AML cell)

Acute myeloid leukemia (AML) cells are malignant, poorly differentiated cells of the myeloid lineage that proliferate uncontrollably in the bone marrow and peripheral blood. These cells arise from hematopoietic stem or progenitor cells that have acquired somatic mutations, leading to a block in differentiation and the evasion of programmed cell death (StatPearls, NIH). While the 'AML cell' itself is a complex biological entity rather than a single molecular target, it serves as the host for numerous therapeutic targets such as FLT3, IDH1/2, and BCL-2 (NCI, NIH). Modern precision medicine approaches focus on identifying specific genetic aberrations within these cells to tailor inhibitor therapies, such as using gilteritinib for FLT3-mutated blasts or venetoclax to exploit BCL-2 dependency (PubMed, PMCID: PMC7235454). Effective treatment aims to eradicate these leukemic clones while minimizing damage to healthy hematopoietic stem cells, though this remains a challenge due to clonal evolution and drug resistance (Leukemia & Lymphoma Society).

Other names

MyeloblastAML blastLeukemic blastMalignant myeloid precursor

Drugs targeting components of acute myeloid leukemia cells act through various mechanisms including DNA synthesis inhibition (antimetabolites), induction of apoptosis via BCL-2 inhibition, inhibition of oncogenic tyrosine kinases (e.g., FLT3), and restoration of cellular differentiation through inhibition of mutant enzymes (e.g., IDH1/2).